Xilio Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | $-35.0M | $-58.2M | $-76.4M | $-88.2M | $-75.8M | $-55.2M |
| Depreciation & Amortization | $1.5M | $1.6M | $1.9M | $1.8M | $1.5M | $1.1M |
| Depreciation | $1.5M | $1.6M | $1.8M | $1.7M | $1.4M | $1.1M |
| Amortization | — | — | — | — | — | — |
| Stock-Based Compensation | $6.9M | $6.4M | $7.4M | $8.4M | $5.0M | $1.3M |
| Net Cash from Operating Activities | $-5.0M | $-18.4M | $-68.6M | $-75.7M | $-80.8M | $-36.1M |
| Investing Activities | ||||||
| Capital Expenditures | $518.0K | $36.0K | $486.0K | $1.9M | $1.1M | $2.2M |
| Business Acquisitions | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-518.0K | $-36.0K | $-486.0K | $-1.9M | $-1.1M | $-2.2M |
| Financing Activities | ||||||
| Dividends Paid | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — |
| Net Cash from Financing Activities | $87.8M | $29.2M | $-6.6M | $-69.0K | $260.7M | $10.0M |
| Net Change in Cash | $82.3M | $10.8M | $-75.7M | $-77.7M | $178.8M | $-28.3M |
| Free Cash Flow | $-5.5M | $-18.4M | $-69.1M | $-77.6M | $-81.9M | $-38.3M |